Table 2.
Baseline characteristics of trial participants according to high-risk vs low-risk and high-benefit vs low-benefit
| Variables | High-risk vs low-risk |
High-benefit vs low-benefit |
||
|---|---|---|---|---|
| High-risk | Low-risk | High-benefit | Low-benefit | |
| SBP ≥130 mmHg | SBP <130 mmHg | ITE >0 | ITE ≤0 | |
| (N = 7943) | (N = 2729) | (N = 8563) | (N = 2109) | |
| Age, mean (SD), years | 65.8 (8.6) | 64.6 (8.0) | 65.9 (8.7) | 63.6 (7.1) |
| Female, % | 3281 (41.3) | 1071 (39.3) | 3633 (42.4) | 719 (34.1) |
| Race/ethnicity, % | ||||
| Non-Hispanic White | 4613 (58.1) | 1654 (60.6) | 5011 (58.6) | 1256 (59.6) |
| Non-Hispanic Black | 2096 (26.4) | 751 (27.5) | 2350 (27.4) | 497 (23.6) |
| Hispanic | 777 (9.8) | 191 (7.0) | 790 (9.2) | 178 (8.4) |
| Other | 457 (5.7) | 133 (4.9) | 412 (4.8) | 178 (8.4) |
| Education status, % | ||||
| Less than college | 5303 (66.8) | 1827 (67.0) | 5675 (66.3) | 1455 (69.0) |
| College or above | 2640 (33.2) | 902 (33.0) | 2888 (33.7) | 654 (31.0) |
| Uninsured, % | 1043 (13.1) | 296 (10.9) | 1016 (11.9) | 323 (15.3) |
| Living alone, % | 2006 (25.3) | 693 (25.4) | 2182 (25.5) | 517 (24.5) |
| Smoking, % | 1005 (12.7) | 390 (14.3) | 1111 (13.0) | 284 (13.5) |
| SBP, mean (SD), mmHg | 145.7 (12.5) | 120.9 (7.0) | 139.4 (16.4) | 139.2 (12.3) |
| BMI, mean (SD), kg/m2 | 30.9 (5.3) | 31.5 (5.3) | 31.2 (5.2) | 30.6 (5.6) |
| Total cholesterol, mean (SD), mg/dL | 192.5 (42.5) | 187.8 (42.4) | 190.8 (42.0) | 193.4 (44.5) |
| HDL cholesterol, mean (SD), mg/dL | 50.2 (14.6) | 48.7 (13.7) | 51.4 (14.5) | 43.6 (12.3) |
| eGFR, mL/min/1.73 m2, % | ||||
| ≥90 | 2317 (29.2) | 770 (28.2) | 2405 (28.1) | 682 (32.3) |
| 60 to <90 | 3963 (50.0) | 1368 (50.1) | 4306 (50.3) | 1025 (48.6) |
| 45 to <60 | 1154 (14.5) | 2333 (15.0) | 1274 (14.9) | 290 (13.8) |
| <45 | 509 (6.4) | 1210 (6.7) | 578 (6.7) | 112 (5.3) |
| Clinical CVD, % | 1774 (22.3) | 652 (23.9) | 1609 (18.8) | 817 (38.7) |
| Statin use, % | 4071 (51.3) | 1582 (58.0) | 4400 (51.4) | 1253 (59.4) |
| Anti-hypertensive use, % | ||||
| 0 | 910 (11.5) | 203 (7.4) | 874 (10.2) | 239 (11.3) |
| 1 | 2640 (33.2) | 946 (34.7) | 2854 (33.3) | 732 (34.7) |
| ≥2 | 4393 (55.3) | 1580 (57.9) | 4835 (56.5) | 1138 (54.0) |
| History of diabetesa | 3316 (41.8) | 1167 (42.8) | 3289 (38.4) | 1194 (56.6) |
| 10-year Framingham CVD risk %, median (IQR) | 25.1 (20.3) | 16.5 (14.6) | 21.7 (18.7) | 27.3 (24.1) |
| 10-year ASCVD risk %, median (IQR) | 21.9 (19.4) | 14.8 (13.3) | 19.6 (18.2) | 20.6 (17.0) |
BMI, body mass index; SBP, systolic blood pressure; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease; SD, standard deviation; IQR, interquartile range; ASCVD, atherosclerotic cardiovascular disease; ITE, intensive treatment effect.
a
History of diabetes was labelled as 0 for the SPRINT (Systolic Blood Pressure Intervention Trial) participants and 1 for the ACCORD-BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) participants.